Role of thermodynamic and kinetic parameters in gadolinium chelate stability

In recent years there has been a renewed interest in the physicochemical properties of gadolinium chelates (GC). The aim of this review is to discuss the physicochemical properties of marketed GC with regard to possible biological consequences. GC can be classified according to three key molecular features: 1) the nature of the chelating moiety: either macrocyclic molecules in which Gd3+ is caged in the preorganized cavity of the ligand, or linear, open‐chain molecules; 2) ionicity: the ionicity of the molecule varies from neutral to tri‐anionic agents; and 3) the presence or absence of an aromatic lipophilic moiety, which has a profound impact on the biodistribution of the GC. These parameters can also explain why GC differ considerably with regard to their thermodynamic stability constants and kinetic stability, as demonstrated by numerous studies. The concept of thermodynamic and kinetic stability is critically discussed, as it remains somewhat controversial, especially in predicting the amount of free gadolinium that may result from decomplexation of chelates in physiologic or pathologic situations. This review examines the possibility that the high kinetic stability provided by the macrocyclic structure combined with a high thermodynamic stability (reinforced by ionicity for macrocyclic chelates) can minimize the amount of free Gd3+ released in the body. J. Magn. Reson. Imaging 2009;30:1249–1258. © 2009 Wiley‐Liss, Inc.

[1]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[2]  D. Løvhaug,et al.  Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.

[3]  R. Swartz,et al.  Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.

[4]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[5]  E. Lancelot,et al.  Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. , 2008, Toxicology.

[6]  S. Morcos,et al.  Extracellular gadolinium contrast agents: differences in stability. , 2008, European journal of radiology.

[7]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[8]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[9]  L. Skov,et al.  Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.

[10]  P. Kuo Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. , 2008, Journal of the American College of Radiology : JACR.

[11]  M. Perazella,et al.  Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. , 2008, Current drug safety.

[12]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008, Expert opinion on drug metabolism & toxicology.

[13]  O. Döhr,et al.  Preclinical Safety Evaluation of Gd-EOB-DTPA (Primovist) , 2007, Investigative radiology.

[14]  Frank J Rybicki,et al.  Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[15]  Charu Thakral,et al.  Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. , 2007, Contrast media & molecular imaging.

[16]  H. Schmitt-Willich Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.

[17]  S. Morcos,et al.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[18]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[19]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[20]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[21]  T. Steger-Hartmann,et al.  Preclinical Safety Assessment of Vasovist (Gadofosveset trisodium), a New Magnetic Resonance Imaging Contrast Agent for Angiography , 2006, Investigative radiology.

[22]  Sophie Laurent,et al.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.

[23]  T. Grobner Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[25]  V. Lorusso,et al.  Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. , 2006, Contrast media & molecular imaging.

[26]  M. D. de Broe,et al.  Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. , 2005, Kidney international.

[27]  M. Port,et al.  Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence , 2004, Chemistry.

[28]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[29]  M. Wastie,et al.  Gadolinium: named after Finland's most famous chemist. , 2004, The British journal of radiology.

[30]  C. Corot,et al.  Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation , 1998, Biometals.

[31]  K. Kent,et al.  Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.

[32]  E. Brücher Kinetic Stabilities of Gadolinium(III) Chelates Used as MRI Contrast Agents , 2002 .

[33]  G. Choppin,et al.  Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. , 2001, Inorganic chemistry.

[34]  S. Laurent,et al.  Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.

[35]  E.,et al.  Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .

[36]  C. de Haën Conception of the first magnetic resonance imaging contrast agents: a brief history. , 2001, Topics in magnetic resonance imaging : TMRI.

[37]  E. Brücher,et al.  The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. , 2000, Chemistry.

[38]  W. Heindel,et al.  Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. , 2000, Investigative radiology.

[39]  A. Pałasz,et al.  Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.

[40]  M. Port,et al.  Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.

[41]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[42]  S. Swan,et al.  Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.

[43]  A. Bianchi,et al.  Interaction of ATP with a Gd3+ complex employed as paramagnetic contrast agent in NMR imaging , 1999 .

[44]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[45]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[46]  A. Reid,et al.  Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.

[47]  Krishan Kumar Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents , 1997 .

[48]  W. Gibby,et al.  Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.

[49]  Éva Tóth,et al.  Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate , 1996 .

[50]  S. Hirano,et al.  Exposure, metabolism, and toxicity of rare earths and related compounds. , 1996, Environmental health perspectives.

[51]  M. Tweedle,et al.  Synthesis, Stability, and Crystal Structure Studies of Some Ca2+, Cu2+, and Zn2+ Complexes of Macrocyclic Polyamino Carboxylates , 1995 .

[52]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[53]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[54]  P. Anelli,et al.  Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Characterization of the Ligand BOPTA and Its Ln(III) Complexes (Ln = Gd, La, Lu). X-ray Structure of Disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa- 5,8,11-triazatridecan-13-oato(5-)]gadolinate(2 , 1995 .

[55]  J. Raymond,et al.  Aluminum‐Induced DNA synthesis in osteobalsts: Mediation by a G‐protein coupled cation sensing mechanism , 1994, Journal of cellular biochemistry.

[56]  I. Lázár,et al.  Kinetics of Formation and Dissociation of Lanthanide(III)-DOTA Complexes , 1994 .

[57]  M. Tweedle,et al.  Equilibrium and Kinetic Studies of Lanthanide Complexes of Macrocyclic Polyamino Carboxylates , 1993 .

[58]  T. J. Norman,et al.  Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications , 1993 .

[59]  T. Norman,et al.  Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. , 1993, Magnetic resonance imaging.

[60]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.

[61]  Xiangyun Wang,et al.  A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent , 1992 .

[62]  S. Quay,et al.  A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.

[63]  J. Hagan,et al.  Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.

[64]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.

[65]  C. Evans The Occurrence and Metabolism of Lanthanides , 1990 .

[66]  M. Schaefer,et al.  Gd‐DOTA, A Potential MRI Contrast Agent Current Status of Physicochemical Knowledge , 1988, Investigative radiology.

[67]  P. Barthelemy,et al.  Highly stable lanthanide macrocyclic complexes: in search of new contrast agents for NMR imaging. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[68]  D. Williams,et al.  Chelating agents in medicine. , 1982, Journal of toxicology. Clinical toxicology.

[69]  D. P. Mellor,et al.  CHAPTER 1 – Historical Background and Fundamental Concepts , 1964 .